Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16271249 | 0.79 | PNMT (0.37) | PNMTADRA2AADRA2BADRA2CKDM4E | |
| SCHEMBL16267617 | 0.78 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL21496903 | 0.78 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29570993 | 0.76 | CXCR4 (0.32) | PNMTADRA2AADRA2BADRA2CKCNH2 | |
| SCHEMBL16267704 | 0.76 | CXCR4 (0.32) | PNMTADRA2AADRA2BADRA2CKCNH2 | |
| SCHEMBL29886302 | 0.72 | — | — | |
| SCHEMBL16267716 | 0.71 | PNMT (0.53) | PNMTADRA2A | |
| SCHEMBL21489595 | 0.71 | PNMT (0.53) | PNMTADRA2A | |
| SCHEMBL29652240 | 0.71 | PNMT (0.53) | PNMTADRA2A | |
| SCHEMBL25251593 | 0.71 | ABHD6 (0.36) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503442-B2 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4263522-B1 | DIHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2024-10-02 | — | — | EP | disclosed |
| EP-4263517-B1 | A SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVE AS A D1 POSITIVE ALLOSTERIC MODULATOR | UCB Biopharma SRL (BE) | 2024-10-02 | — | — | EP | disclosed |
| CN-111971282-B | Pyrazolotetrahydroisoquinoline derivatives as dopamine D1 receptor positive modulators | 伊莱利利公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20240083875-A1 | DIHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-14 | — | — | US | disclosed |
| US-20240059665-A1 | A Substituted Tetrahydroisoquinoline Derivative As A D1 Positive Allosteric Modulator | UCB Biopharma SRL (BE) | 2024-02-22 | — | — | US | disclosed |
| EP-4200280-B1 | PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | LILLY CO ELI (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | UCB Biopharma SRL (BE) | 2024-02-08 | — | — | US | disclosed |
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY | 2023-11-30 | — | — | US | disclosed |
| EP-4263522-A1 | DIHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-116601146-A | Phenyl-3, 4-dihydroisoquinolin-2 (1H) -yl-ethan-1-one derivatives as positive allosteric modulators of dopamine D1 receptor | 伊莱利利公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3781560-B1 | PYRAZO-TETRAHYDROISOQUINOLINE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE MODULATORS | LILLY CO ELI (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220259179-A1 | A Substituted Tetrahydroisoquinoiline Derivative as a D1 Positive Allosteric Modulator | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-08-18 | — | — | US | disclosed |
| WO-2022129303-A1 | DIHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-3781560-A1 | PYRAZO-TETRAHYDROISOQUINOLINE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE MODULATORS | Eli Lilly and Company (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-111971282-A | Pyrazolotetrahydroisoquinoline derivatives as positive modulators of dopamine D1 receptor | 伊莱利利公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10611751-B2 | Dopamine D1 receptor positive allosteric modulators | ELI LILLY AND COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2019204418-A1 | PYRAZO-TETRAHYDROISOQUINOLINE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE MODULATORS | ELI LILLY AND COMPANY (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190322639-A1 | DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ELI LILLY AND COMPANY | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | PNMT 173/4885ADRA2A 35/4885ADRA2B 66/4885 |
| US-12503442-B2 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | PNMT 173/4885ADRA2A 35/4885ADRA2B 66/4885 |
| US-20220259179-A1 | A Substituted Tetrahydroisoquinoiline Derivative as a D1 Positive Allosteric Modulator | OPRD1, ADRA1D, GPR52 | PNMT 963/4885ADRA2A 31/4885ADRA2B 22/4885 |
| US-20240083875-A1 | DIHYDROISOQUINOLINYL DERIVATIVES | OPRD1, GPER1, ADRA1D | PNMT 1691/4885ADRA2A 17/4885ADRA2B 26/4885 |
| US-20240059665-A1 | A Substituted Tetrahydroisoquinoline Derivative As A D1 Positive Allosteric Modulator | OPRD1, ADRA1D, GPR52 | PNMT 1516/4885ADRA2A 9/4885ADRA2B 15/4885 |
| US-10611751-B2 | Dopamine D1 receptor positive allosteric modulators | ADRA1D, DRD2, HTR1D | PNMT 422/4885ADRA2A 32/4885ADRA2B 66/4885 |
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | OPRD1, OPRK1, OPRL1 | PNMT 1508/4885ADRA2A 19/4885ADRA2B 32/4885 |
| US-20190322639-A1 | DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ADRA1D, DRD2, HTR1D | PNMT 422/4885ADRA2A 32/4885ADRA2B 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.